This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CSL Behring Launches HizentraA® Co-Pay Relief Program

Stocks in this article: CSL

KING OF PRUSSIA, Pa., May 20, 2014 /PRNewswire/ -- People managing primary immunodeficiency (PI) with CSL Behring's Hizentra ® (Immune Globulin Subcutaneous [Human]) may now be eligible for financial support through the Hizentra ® Co-Pay Relief Program. The new program offers eligible U.S. patients up to $4,000 per year to be applied toward Hizentra co-payments, deductibles and coinsurance. Out-of-pocket therapy costs will be processed seamlessly through the electronic billing systems of specialty pharmacies and physician offices, which means no paperwork is required for the patient, pharmacist or physician.

CSL Behring logo

"CSL Behring is committed to providing medical innovations and supportive services that make a meaningful difference in the lives of people living with a serious health condition," said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. "The Hizentra Co-Pay Relief Program is another example of this commitment and was designed to specifically meet the needs of the primary immunodeficiency community by increasing access to Hizentra."

Enrollment in the Hizentra Co-Pay Relief Program is automated and paperless, and members can access their account online at any time. Patients can contact CSL Behring's IgIQ resource center at 1-877-355-IGIQ (4447) to confirm eligibility and to discuss the steps for enrolling. The program is open to U.S. residents who are at least 2 years old and diagnosed with PI. Participants must have U.S.-based private insurance that covers Hizentra. Individuals covered by state- or federally funded programs, such as Medicare, Medicare Advantage plans, Medicaid, PCIP, Champus, TriCare, and Veterans Administration (VA), are not eligible. 

"For many of the 250,000 people in the U.S. diagnosed with a primary immunodeficiency, immunoglobulin replacement therapy is an essential part of staying healthy," said Marcia Boyle, President and Founder of the Immune Deficiency Foundation. "We applaud CSL Behring for the company's long-standing commitment to the PI community and now for the Hizentra Co-Pay Relief Program, which will make a meaningful difference to those taking CSL Behring's subcutaneous immunoglobulin."   

For more information about the Hizentra Co-Pay Relief Program, please call 1-877-355-IGIQ (4447) or visit www.Hizentra.com/copay.

About Primary Immunodeficiencies

More than 200 types of PIs are recognized by the World Health Organization. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, can even result in death.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,651.86 +294.99 1.70%
S&P 500 2,043.16 +30.27 1.50%
NASDAQ 4,723.4150 +79.1030 1.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs